Born Free Method: The Podcast
Born Free Method: The Podcast
Nathan Riley, MD, Father of 2
Preterm Labor: Prevention and Management
1 hour 8 minutes Posted Feb 4, 2025 at 8:04 pm.
0:00
1:08:20
Download MP3
Show notes

This summary covers:- Prediction and Prevention of Spontaneous Preterm Birth - Practice Bulletin #234 - Published August 2021- Management of Preterm Labor - Practice Bulletin #171 - Published October 2016

Prediction and Prevention

Five Pearls

* PTD at <34 wga carries higher mortality and morbidity risk to newborn in delivery and long-term morbidity

* History of PTD is the greatest risk factor for PTD in a current pregnancy

* Progesterone supplementation can be considered regardless of history of PTD

* In patients w/ singleton pregnancy and history of PTD, cerclage should be offered if CL <25 mm is detected on TVUS at 16-24 wga

* Omega 3s, low-dose aspirin, lifestyle modification, and smoking cessation are also important considerations in decreasing our national PTD rate

Background

* rates of preterm delivery in the U.S. has been pretty stable

* "Although risks are greatest for neonates born before 34 weeks of gestation, infants born after 34 weeks of gestation but before 37 weeks of gestation are still more likely to experience delivery complications, long-term impairment, and early death than those born later in pregnancy"

* risk factors for PTD: prior PTD (1-2x ↑ risk), short cervical length (<20mm if no history of PTD; <25mm if prior history), vaginal infection in pregnancy, vaginal bleeding in pregnancy, UTI in pregnancy, or periodontal disease in pregnancy (treatment of any of these won't normalize risk, though), low maternal BMI, smoking, substance abuse, and short inter-pregnancy interval

* in case you were wondering, history of LEEP of CKC for cervical dysplasia has not been found to be a risk factor after all according to ACOG but there are studies that support this (and my own direct clinical experience reflects the alternative)

* White women have the lowest rate (9.3%), Hispanic women (10%), American Indian and Alaskan native (11.5%), Native Hawaiian and Pacific Islander (11.8%), with highest rates seen among black women (14%)

Who should be screened and how?

* the purpose of screening is to identify patients in whom intervention will be helpful

* really the only patients who qualify for screening are those with a history of prior PTD, PPROM, multiple gestations, but ACOG feels it’s reasonable to screen universally as 5% of all women could potentially give birth preterm

* a systematic review looked at 14 studies and found that:

“a cervical length less than 25 mm before 16-24 weeks of gestation had a sensitivity of 65.4% for preterm birth before 35 weeks of gestation, with a positive predictive value of 33.0% and a negative predictive value of 92.0%. Sub-analysis of the studies that included only women whose risk factor was prior spontaneous preterm birth found a similar sensitivity and a positive predictive value of 41.4%”

* get a baseline transvaginal ultrasound (TVUS) and repeat this evaluation every 1-2 weeks to assess for change (limited data on time interval)

* measure three times, and go with the average

* "fetal fibronectin screening, bacterial vaginosis screening, and home uterine activity monitoring have been proposed to assess a woman’s risk of preterm delivery" and none of them have panned out as useful predictors of PTD in asymptomatic women

* recent data suggests that it might actually be cost-effective to universally screen for shortened cervix in patients without history of PTD (study 1, study 2), but, for now, ACOG states it's reasonable to offer but not necessarily recommended universally

When and how to prevent PTD?

No history of PTD

* Extensively studied as a means to reduce the risk of preterm birth in asymptomatic women with a singleton pregnancy, short cervix, and no prior preterm birth.

* a meta-analysis of five randomized trials of vaginal progesterone versus placebo in patients with a singleton pregnancy, a short cervix, and no prior preterm birth was performed, including patients from the 2019 OPTIMUM (Does Progesterone Prophylaxis to Prevent Preterm Labour Improve Outcome?) trial who did not have other risk factors, and standardizing the threshold definition of shortened cervix at 25 mm or less for their analysis. Patients treated with vaginal progesterone had a significantly reduced risk of any preterm birth before 34 0/7 weeks of gestation (14.5% versus 24.6%; RR, 0.60; 95% CI, 0.44–0.82), spontaneous preterm birth before 34 0/7 weeks of gestation (RR, 0.63; 95% CI, 0.44–0.88), neonatal respiratory distress, and neonatal intensive care unit admission. The meta-analysis authors calculated that 14 patients would need to be treated to prevent one spontaneous preterm birth before 34 0/7 weeks of gestation.

* Vaginal progesterone is recommended for asymptomatic individuals without a history of preterm birth with a singleton pregnancy and a short cervix. 200 mg per vagina nightly is the best studied regimen

History of PTD:

* Before the PROLONG trial (2020), a metaanalysis was published in 1990 that showed demonstrable evidence of the benefits of 17-OH-P in preventing recurrent PTD, which led to a large multicenter RCT of 463 patients. They were randomized to receive either 250 mg 17-OHPC IM or placebo, starting between 16 0/7 and 20 6/7 weeks of gestation. Administration of 17-OHPC reduced the rate of preterm birth before 35 weeks of gestation by one third, leading ACOG and SMFM to recommend this intervention universally to women with history of PTD.

* Then came the PROLONG trial, which evaluated the efficacy of 17-OHPC 250 mg intramuscular injection weekly compared with placebo on preterm birth and neonatal morbidity among women with a singleton pregnancy and prior spontaneous preterm birth. Large, international, multicenter double-blind RCT. 1740 women randomized (of 1877 eligible). No statistical difference found in the two primary outcomes of preterm birth before 35 0/7 weeks of gestation or maternal/neonatal outcomes.

* On April 5, 2023, the FDA withdrew its approval of 17-OHP for prevention of preterm birth as a result of the PROLONG trial

* Data comparing vaginal to IM progesterone supplementation continues to roll in, so no definitive conclusions can be made yet

* In the meantime, SMFM discourages clinicians from using IM 17-OHP off-label

* Recommended to screen cervical length every week from 16-24 weeks and to offer cerclage if it measures <25 mm, though this intervention was best studied for women with history of PTD <34 weeks

* it may be more cost effective to forego cervical shortening screening altogether in those without this history

Cerclage

* Short cervix found on ultrasound: uncertain effectiveness in patients with a short cervix and no history of preterm birth. However, there is evidence of potential benefit in patients with a very short cervical length (<10 mm)

* Open cervix on physical exam: Individuals with cervical insufficiency based on a dilated cervix on a digital or speculum examination at 16 0/7–23 6/7 weeks of gestation are candidates for a physical examination-indicated cerclage (but data is mixed)

* unclear if 17-OH-P plus cerclage are additionally helpful together compared to either intervention alone

* An interesting side note: there’s no evidence, per say, that suggests that it’s a terrible idea to place an US-indicated cerclage after 23 6/7 weeks; this is merely “expert opinion”

* Because cervical insufficiency traditionally is defined as painless cervical dilation in the 2nd trimester, this restriction presented no issue when viability did not begin until the 3rd trimester and indeed may have arisen to discourage the treatment of patients with threatened preterm labor with cerclage

* But now that we have better means of keeping 23+ weekers alive in the NICU, it seems that little investment has been made to prevent babies from coming super early

* What if a specific institution doesn’t have the full capacities for keeping these very preterm babies alive? Should we not then consider an early 3rd trimester cerclage? Why not? Very little data to continue this conversation…(much of this is paraphrased from a bada$$ article that was recently publis…



Get full access to Born Free Method: The Podcast at nathanrileyobgyn.substack.com/subscribe